ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

01 أغسطس 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

29 يوليو 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

29 يوليو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

23 يوليو 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

22 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

09 يوليو 2024 15:53:01 بحسب Nasdaq GlobeNewswire

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

09 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 يوليو 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

10 يونيو 2024 13:30:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 يونيو 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

03 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

14 مايو 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

13 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 مايو 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

29 أبريل 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Appoints David Topper as Chief Financial Officer

10 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 أبريل 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

28 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

11 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

10 مارس 2024 15:00:00 بحسب Nasdaq GlobeNewswire